Fig 1: Serum hormone concentrations: PRL, hPL and GH2 concentrations across gestation are shown for SCOPE (N = 465) and STOP (N = 684) women with uncomplicated pregnancies. Estimated marginal means (±SEM) for SCOPE and STOP women at 10 weeks and 16 weeks of gestation are presented. Serum hormone (PRL, hPL and GH2) concentrations were analysed using a linear mixed effects model, adjusting for gestational age at sampling. Significance is indicated with asterisks (**** p < 0.0001 and *** p < 0.001).
Fig 2: Placental growth hormone (GH2) concentrations stratified by maternal age and BMI: GH2 in early gestation SCOPE (N = 465) and STOP (N = 684) women was stratified by maternal age and BMI status. Women were stratified as younger than 35y or 35y and older and as non-obese (healthy BMI) or obese.
Fig 3: Serum hormone concentrations stratified by FA supplementation: Estimated marginal means for (A) prolactin (PRL), (B) human placental lactogen (hPL) and (C) placental growth hormone (GH2) in SCOPE (14–16 weeks of gestation) and STOP (6–16 weeks) women are stratified by four different FA supplementation categories (SCOPE N = 465; STOP N = 624).
Supplier Page from Wuhan Fine Biotech Co., Ltd. for Human GH2(Growth Hormone 2) ELISA Kit